Geron Corp (GERN.O)

GERN.O on Nasdaq

2.25USD
19 Sep 2014
Price Change (% chg)

$-0.06 (-2.60%)
Prev Close
$2.31
Open
$2.31
Day's High
$2.34
Day's Low
$2.19
Volume
4,186,723
Avg. Vol
2,702,552
52-wk High
$7.36
52-wk Low
$1.31

GERN.O

Chart for GERN.O

About

Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication.... (more)

Overall

Beta: 1.87
Market Cap (Mil.): $353.08
Shares Outstanding (Mil.): 156.92
Dividend: --
Yield (%): --

Financials

  GERN.O Industry Sector
P/E (TTM): -- 144.28 33.56
EPS (TTM): -0.25 -- --
ROI: -32.59 -2.32 17.36
ROE: -32.59 -6.96 18.23
Search Stocks

FDA lifts partial hold on study testing Geron's only drug

- Geron Corp said the U.S. Food and Drug Administration had lifted a partial clinical hold on a study testing its sole drug as a treatment for myelofibrosis, a rare form of blood cancer, sending the company's shares soaring in morning trading.

12 Jun 2014

UPDATE 3-FDA lifts partial hold on study testing Geron's only drug

June 12 - Geron Corp said the U.S. Food and Drug Administration had lifted a partial clinical hold on a study testing its sole drug as a treatment for myelofibrosis, a rare form of blood cancer, sending the company's shares soaring in morning trading.

12 Jun 2014

FDA lifts partial hold on study testing Geron's drug, shares jump

June 12 - Geron Corp said the U.S. Food and Drug Administration lifted a partial clinical hold on a study testing its blood cancer drug, imetelstat, sending its shares soaring about 34 percent in premarket trading.

12 Jun 2014

Geron says FDA halts patient enrollment in another cancer trial

- Geron Corp said the U.S. Food and Drug Administration ordered a halt to new patient enrollments in an early-stage trial of its blood cancer drug, imetelstat, over concerns about liver damage.

20 Mar 2014

Geron says FDA halts patient enrollment in another cancer trial

March 20 - Geron Corp said the U.S. Food and Drug Administration ordered a halt to new patient enrollments in an early-stage trial of its blood cancer drug, imetelstat, over concerns about liver damage.

20 Mar 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks